Key result
NAD⁺ and nicotinamide riboside show no significant benefit for HF hospitalization or mortality.
Why the study?
Does supplementation with exogenous NAD⁺ or nicotinamide riboside improve clinical outcomes (HF hospitalization, mortality) and LVEF in adults with symptomatic heart failure?
Meta-Analysis (n=387)
Does supplementation with exogenous NAD⁺ or nicotinamide riboside improve clinical outcomes (HF hospitalization, mortality) and LVEF in adults with symptomatic heart failure?
Exogenous NAD⁺ and nicotinamide riboside supplementation did not significantly improve LVEF, biomarkers, HF hospitalization, or mortality in adults with heart failure, while raising a potential safety signal regarding increased serum creatinine.
Answers are grounded in this paper and cite their sources.
Supplementation lacks benefit on HF hospitalization or mortality; challenges NAD+ repletion as a therapeutic target and should not change practice.
Mitochondrial dysfunction and NAD⁺ depletion contribute to heart failure (HF), but trials of NAD⁺ and nicotinamide riboside (NR) have shown inconsistent results. We systematically evaluated their effects on cardiac function, biomarkers, clinical outcomes, and safety in adults with symptomatic HF. A systematic search was conducted through PubMed, Embase, Scopus, Web of Science, and Cochrane from inception to September 2025. Adults with HF receiving guideline-directed therapy were included. Interventions comprised intravenous NAD⁺ or oral NR versus placebo. Primary outcomes were HF hospitalization, all-cause mortality, and change in left ventricular ejection fraction (LVEF). Secondary outcomes included cardiac structural and functional measures, biomarkers, and laboratory safety outcomes. Random-effects meta-analyses were performed using Review Manager version 5.4.1. Four randomized controlled trials involving 387 patients were included. NAD⁺-related interventions did not significantly reduce HF hospitalization (3 studies, 268 patients; RR = 0.63, 95% CI 0.36-1.09; P = 0.10; I2 = 0%) or mortality (2 studies, 238 patients; RR = 0.51, 95% CI 0.09-2.86; P = 0.45; I2 = 0%). No significant differences were observed in LVEF at 1 month (2 studies, 238 patients; MD = 2.10%, 95% CI - 0.18 to 4.38; P = 0.07; I2 = 0%), 3 months (2 studies, 87 patients; MD = - 0.48%, 95% CI - 4.74 to 3.78; P = 0.83; I2 = 0%), or last follow-up (3 studies, 267 patients; MD = 1.54%, 95% CI - 0.69 to 3.77; P = 0.18; I2 = 4%). No significant differences were observed in global longitudinal strain (GLS) (2 studies, 89 patients; MD = 0.03, 95% CI - 2.10 to 2.16; P = 0.96; I2 = 61%), left atrial diameter (LAD) (2 studies, 240 patients; MD = - 0.29 mm, 95% CI - 1.80 to 1.22; P = 0.71; I2 = 0%), left ventricular end-diastolic diameter (LVEDD) (2 studies, 240 patients; MD = 0.24 mm, 95% CI - 2.25 to 2.73; P = 0.85; I2 = 18%), or left ventricular end-diastolic volume (LVEDV) (2 studies, 202 patients; MD = 10.08 mL, 95% CI - 23.55 to 43.70; P = 0.56; I2 = 66%). N-terminal pro-B-type natriuretic peptide (NT-proBNP) did not differ significantly between groups (2 studies, 238 patients; MD = - 382.76 pg/mL, 95% CI - 1091.62 to 326.11; P = 0.29; I2 = 0%). Serum creatinine increased significantly with NAD⁺ (2 studies, 209 patients; MD = 7.46 μmol/L, 95% CI 2.21-12.71; P = 0.005; I2 = 48%), whereas alanine aminotransferase (ALT) did not differ significantly between groups (2 studies, 209 patients; MD = 1.62 U/L, 95% CI - 3.18 to 6.42; P = 0.51; I2 = 81%). NAD⁺ and NR did not significantly improve cardiac function, biomarkers, or clinical outcomes in adults with symptomatic HF, although numerical trends favored treatment. The interventions appeared generally well tolerated in the short term, but the observed increase in serum creatinine warrants further evaluation. Larger, longer-term randomized controlled trials are needed to clarify their clinical efficacy and safety in HF. PROSPERO Registration: CRD420251251462.
No takes yet. Share an insight, caveat, or question.
Hamzah et al. (2026) conducted a meta-analysis in Symptomatic heart failure (n=387). Intravenous NAD⁺ or oral nicotinamide riboside (NR) vs. Placebo was evaluated on Heart failure hospitalization, all-cause mortality, and change in left ventricular ejection fraction (LVEF) (RR 0.63, 95% CI 0.36-1.09, p=0.10). NAD⁺ and nicotinamide riboside did not reduce HF hospitalization or mortality in adults with symptomatic HF.
Synapse has enriched 10 related papers. Consider them for comparative context: